HIV/AIDS Clinical Care: Meetings

Report from the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention

• HIV/AIDS Clinical Care
• Meeting Report
• Free Article

Our physician-editors detail the most important findings from this year's meeting

• By ACC Editors
• August 31, 2009

Early ART Initiation Improves Survival in Resource-Limited Settings

• HIV/AIDS Clinical Care
• Meeting Report
• Free Article

New findings from Haiti (described at IAS 2009) support starting ART when CD4 counts fall below 350 cells/mm³ — the same threshold that is recommended in resource-rich settings.

• By Gerald H. Friedland, MD
• August 31, 2009

Maternal ART Reduces Transmission of HIV through Breast-Feeding

• HIV/AIDS Clinical Care
• Meeting Report
• Free Article

In a study conducted in Botswana (and reported at IAS 2009), the rate of mother-to-child transmission was only 1% among breast-feeding women who received ART through 6 months postpartum.

• By Judith Feinberg, MD
• August 31, 2009

Nevirapine vs. Boosted Atazanavir — The ARTEN Study

• HIV/AIDS Clinical Care
• Meeting Report
• Subscription Required

The combination of nevirapine + tenofovir + FTC (or 3TC) is safe and effective in treatment-naive patients, according to data presented at IAS 2009.

• By Paul E. Sax, MD
• August 31, 2009

GSK572 — A "Next-Generation" Integrase Inhibitor?

• HIV/AIDS Clinical Care
• Meeting Report
• Subscription Required

Early data presented at IAS 2009 are encouraging.

• By Charles B. Hicks, MD
• August 31, 2009

Abacavir and CVD — Again

• HIV/AIDS Clinical Care
• Meeting Report
• Subscription Required

One large study presented at IAS 2009 supported an association between abacavir and cardiovascular risk, but another did not.

• By Paul E. Sax, MD
• August 31, 2009

Strategies for Antiretroviral Deintensification

• HIV/AIDS Clinical Care
• Meeting Report
• Subscription Required

Data presented at IAS 2009 highlighted new approaches to PI therapy for patients with virologic suppression, including simplifying ritonavir-boosted atazanavir to unboosted atazanavir and trying to sustain suppression using darunavir without nucleosides. Success rates differed among these strategies.

• By Charles B. Hicks, MD
• August 31, 2009

ALTAIR — The End of NRTI-Only Regimens

• HIV/AIDS Clinical Care
• Meeting Report
• Subscription Required

In a randomized study, standard combination therapy was preferable to a quadruple-NRTI regimen in terms of both virologic control and adverse effects.

• By Helmut Albrecht, MD
• August 31, 2009

Report from the XVIII International HIV Drug Resistance Workshop

• HIV/AIDS Clinical Care
• Meeting Report
• Free Article

An expert's take on the most clinically relevant reports from this year's resistance meeting

• By Daniel R. Kuritzkes, MD
• August 24, 2009

No Clinical Benefit from Adding IL-2 to ART

• HIV/AIDS Clinical Care
• Meeting Report
• Free Article

In two large trials presented at CROI 2009, CD4-cell increases were greater with IL-2 and ART together than with ART alone, but these increases did not lead to reductions in morbidity or mortality.

• By Keith Henry, MD
• March 9, 2009